| Name | Title | Contact Details |
|---|
Abilities Foundation of Nova Scotia is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MedShift, founded in 2015 in Charlotte, NC delivers platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 250 providers in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems. MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians and their business. MedShift`s broad portfolio of services for practices includes a portfolio of 24 leading aesthetic medical devices from six manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers MedShift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across manufacturer and provider spectrum and continues to empower robust integration with leading brands and doctors in the industry.
Veatch Ophthalmic Instruments is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shamrock Marketing De, Inc. is a Chino, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.